换一批Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
第一作者：
Kathrin,Zitzmann
第一单位：
Department of Internal Medicine II, University-Hospital Munich-Grosshadern, University of Munich, Marchioninistr.15, 81377 Munich, Germany.
作者：
主题词
抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);细胞存活(Cell Survival);剂量效应关系, 药物(Dose-Response Relationship, Drug);细胞外信号调节MAP激酶类(Extracellular Signal-Regulated MAP Kinases);反馈, 生理(Feedback, Physiological);G1期(G1 Phase);人类(Humans);咪唑类(Imidazoles);细胞内信号肽和蛋白质类(Intracellular Signaling Peptides and Proteins);MAP激酶信号系统(MAP Kinase Signaling System);神经内分泌瘤(Neuroendocrine Tumors);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);磷酰化(Phosphorylation);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);嘧啶类(Pyrimidines);吡咯类(Pyrroles);喹啉类(Quinolines);信号传导(Signal Transduction);西罗莫司(Sirolimus);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases);血管内皮生长因子A(Vascular Endothelial Growth Factor A);raf激酶类(raf Kinases)
DOI
10.1016/j.canlet.2010.02.018
PMID
20356670
发布时间
2021-12-03
- 浏览15
Cancer letters
100-9页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
